Abstract
Familial amyloid polyneuropathy (FAP) is a progressive systemic autosomal dominant disease caused by pathogenic mutations in the transthyretin (TTR) gene. We studied clinical, electrophysiological, histopathological, and genetic characteristics in 15 (13 late-onset and two early-onset) patients belonging to 14 families with polyneuropathy and mutations in TTR. In comparison, we analysed the features of nine unrelated patients with an idiopathic polyneuropathy, in whom TTR mutations have been excluded. Disease occurrence was familial in 36 % of the patients with TTR-associated polyneuropathy and the late-onset type was observed in 86 % (mean age at onset 65.5 years). Clinically, all late-onset TTR-mutant patients presented with distal weakness, pansensory loss, absence of deep tendon reflexes, and sensorimotor hand involvement. Afferent-ataxic gait was present in 92 % leading to wheelchair dependence in 60 % after a mean duration of 4.6 years. Autonomic involvement was observed in 60 %, and ankle edema in 92 %. The sensorimotor polyneuropathy was from an axonal type in 82 %, demyelinating or mixed type in 9 % each. Compared to the TTR-unmutated idiopathic polyneuropathy patients, we identified rapid progression, early ambulatory loss, and autonomic disturbances, associated with a severe polyneuropathy as red flags for TTR–FAP. In 18 % of the late-onset TTR-FAP patients, no amyloid was found in nerve biopsies. Further diagnostic pitfalls were unspecific electrophysiology, and coincident diabetes mellitus (23 %) or monoclonal gammopathy (7 %). We conclude that a rapid disease course, severely ataxic gait, hand involvement, and autonomic dysfunction are diagnostic hallmarks of late-onset TTR–FAP. Genetic analysis should be performed even when amyloid deposits are lacking or when polyneuropathy-causing comorbidities are concomitant.
Similar content being viewed by others
References
Andrade C (1952) A peculiar form of peripheral neuropathy. Brain 75:408–427
Schönland SO, Hegenbart U, Bochtler T et al (2012) Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood 119:488–493
Sommer C, Schröder JM (1989) Amyloid neuropathy: immunocytochemical localization of intra- and extracellular immunoglobulin light chains. Acta Neuropathol 79:190–199
Linke RP (2012) On typing amyloidosis using immunohistochemistry. Detailed illustrations, review and a note on mass spectrometry. Prog Histochem Cytochem 47:61–132
Liz MA, Mar FM, Franquinho F, Sousa MM (2010) Aboard transthyretin: from transport to cleavage. IUBMB Life 62:429–435
Costa PP, Figueira AS, Bravo FR (1978) Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy. Proc Natl Acad Sci USA 75:4499–4503
Cardoso I, Goldsbury CS, Müller SA et al (2002) Transthyretin fibrillogenesis entails the assembly of monomers: a molecular model for in vitro assembled transthyretin amyloid-like fibrils. J Mol Biol 317:683–695
Quintas A, Vaz DC, Cardoso I, Saraiva MJ, Brito RMM (2001) Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J Biol Chem 276:27207–27213
Planté-Bordeneuve V, Said G (2011) Familial amyloid polyneuropathy. Lancet Neurol 10:1086–1097
Conceiçao I, De Carvalho M (2007) Clinical variability in type I familial amyloid polyneuropathy (Val30 Met): comparison between late- and early-onset cases in Portugal. Muscle Nerve 35:116–118
Hund E, Linke RP, Willig F, Grau A (2001) Transthyretin-associated neuropathic amyloidosis. Pathogenesis and treatment. Neurology 56:431–435
Westermark P, Sletten K, Johansson B, Cornwell GG (1990) Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA 87:2843–2845
Bulawa CE, Connelly S, DeVit M et al (2012) Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA 109:9629–9634
Coelho T, Maia L, da Martins Silva A (2010) Tafamidis (Fx-1006A): a first-in-class disease-modifying therapy for transthyretin familial amyloid polyneuropathy. Amyloid 17:75–76
Said G, Grippon S, Kirkpatrick P (2012) Tafamidis. Nat Rev Drug Discov 11:185–186
Holmgren G, Steen L, Ekstedt J et al (1991) Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet 40:242–246
Holmgren G, Steen L, Suhr O et al (1993) Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 341:1113–1116
Dubowitz V, Sewry C (2007) Histological and histochemical stains and reactions. Muscle biopsy a practical approach. Elsevier, Philadelphia, pp 3–39
Schröder JM, Hoheneck M, Weis J, Deist H (1985) Ethylene oxide polyneuropathy: clinical follow-up study with morphometric and electron microscopic findings in a sural nerve biopsy. J Neurol 232:83–90
Weis J, Brandner S, Lammens M, Sommer C, Vallat J-M (2012) Processing of nerve biopsies: a practical guide for neuropathologists. Clin Neuropathol 31:7–23
Benson MD, Kincaid JC (2007) The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 36:411–423
Jacobson DR, Pastore RD, Yaghoubian R et al (1997) Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 336:466–473
Mathis S, Magy L, Diallo L, Boukhris S, Vallat JM (2012) Amyloid neuropathy mimicking chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 45:26–31
Cappellari M, Cavallaro T, Ferrarini M et al (2011) Variable presentations of TTR-related familial amyloid polyneuropathy in seventeen patients. J Peripher Nerv Syst 16:119–129
Palaninathan SK, Mohamedmohaideen NN, Snee WC, Kelly JW, Sacchettini JC (2008) Structural insight into pH-induced conformational changes within the native human transthyretin tetramer. J Mol Biol 382:1157–1167
Wilkinson-White LE, Easterbrook-Smith SB (2007) Characterization of the binding of Cu(II) and Zn(II) to transthyretin: effects on amyloid formation. Biochemistry 46:9123–9132
Zhang Q, Kelly JW (2005) Cys-10 mixed disulfide modifications exacerbate transthyretin familial variant amyloidogenicity: a likely explanation for variable clinical expression of amyloidosis and the lack of pathology in C10S/V30M transgenic mice? Biochemistry 44:9079–9085
Almeida MR, Alves IL, Terazaki H, Ando Y, Saraiva MJ (2000) Comparative studies of two transthyretin variants with protective effects on familial amyloidotic polyneuropathy: TTR R104H and TTR T119 M. Biochem Biophys Res Commun 270:1024–1028
Hammarström P, Jiang X, Hurshman Babbes AR, Powers ET, Kelly JW (2002) Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity. Proc Natl Acad Sci USA 99:16427–16432
Hurshman Babbes AR, Powers ET, Kelly JW (2008) Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis. Biochemistry 47:6969–6984
Soares ML, Coelho T, Sousa A et al (2005) Susceptibility and modifier genes in Portuguese transthyretin V30 M amyloid polyneuropathy: complexity in a single-gene disease. Hum Mol Genet 14:543–553
Sousa MM, Du Y, Fernandes R, Guimarães A, Stern D, Saraiva MJ (2001) Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways. J Neurosci 21:7576–7586
Sousa MM, Saraiva MJ (2003) Neurodegeneration in familial amyloid polyneuropathy: from pathology to molecular signaling. Prog Neurobiol 71:385–400
Koike H (2002) Type I (transthyretin met30) familial amyloid polyneuropathy in japan: early- vs late-onset form. Arch Neurol 59:1771–1776
Koike H, Sobue G (2012) Late-onset familial amyloid polyneuropathy in Japan. Amyloid 19:55–57
Koike H, Misu K, Sugiura M et al (2004) Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy. Neurology 63:129–138
Koike H, Ando Y, Ueda M et al (2009) Distinct characteristics of amyloid deposits in early- and late-onset transthyretin Val30Met familial amyloid polyneuropathy. J Neurol Sci 287:178–184
Monteiro FA, Sousa MM, Cardoso I, do Amaral JB, Guimarães A, Saraiva MJ (2006) Activation of ERK1/2 MAP kinases in familial amyloidotic polyneuropathy. J Neurochem 97:151–161
Monteiro FA, Cardoso I, Sousa MM, Saraiva MJ (2006) In vitro inhibition of transthyretin aggregate-induced cytotoxicity by full and peptide derived forms of the soluble receptor for advanced glycation end products (RAGE). FEBS Lett 580:3451–3456
Sousa MM, Yan SD, Stern D, Saraiva MJ (2000) Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor kB (NF-kB) activation. Lab Invest 80:1101–1110
Sousa MM, Fernandes R, Palha JA, Taboada A, Vieira P, Saraiva MJ (2002) Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin Leu55Pro. Am J Pathol 161:1935–1948
Stern D, Du Yan S, Fang Yan S, Marie Schmidt A (2002) Receptor for advanced glycation end products: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev 54:1615–1625
Kodaira M, Sekijima Y, Tojo K et al (2008) Non-senile wild-type transthyretin systemic amyloidosis presenting as bilateral carpal tunnel syndrome. J Peripher Nerv Syst 13:148–150
Comenzo RL, Zhou P, Fleisher M, Clark B, Teruya-Feldstein J (2006) Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins. Blood 107:3489–3491
Suhr OB, Ericzon B-G (2012) Selection of hereditary transthyretin amyloid patients for liver transplantation: the Swedish experience. Amyloid 19:78–80
Koike H, Kawagashira Y, Iijima M et al (2008) Electrophysiological features of late-onset transthyretin Met30 familial amyloid polyneuropathy unrelated to endemic foci. J Neurol 255:1526–1533
Acknowledgments
We thank the personnel of the Department of Neurology and the Institute of Neuropathology at the University Hospital Aachen (Germany), and particularly Astrid Knischewski and Hannelore Mader, for their technical assistance, and Prof Klaus Altland for valuable information. We are grateful to the patients and their families for their participation in our study.
Conflicts of interest
The authors declare that they have no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Dohrn, M.F., Röcken, C., De Bleecker, J.L. et al. Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy. J Neurol 260, 3093–3108 (2013). https://doi.org/10.1007/s00415-013-7124-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-013-7124-7